1141 related articles for article (PubMed ID: 11586500)
1. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
2. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe (Schering-Plough).
Meng CQ
Curr Opin Investig Drugs; 2001 Mar; 2(3):389-92. PubMed ID: 11575710
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
6. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
7. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
[TBL] [Abstract][Full Text] [Related]
8. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors unmask cryptic regulatory mechanisms.
Lopez D; Chambers CM; Ness GC
Arch Biochem Biophys; 1997 Jul; 343(1):118-22. PubMed ID: 9210653
[TBL] [Abstract][Full Text] [Related]
9. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
10. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
12. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
13. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.
Lyseng-Williamson KA
Am J Cardiovasc Drugs; 2012 Feb; 12(1):49-56. PubMed ID: 22208355
[TBL] [Abstract][Full Text] [Related]
15. Combination of fish oil and fish protein hydrolysate reduces the plasma cholesterol level with a concurrent increase in hepatic cholesterol level in high-fat-fed Wistar rats.
Wergedahl H; Gudbrandsen OA; Røst TH; Berge RK
Nutrition; 2009 Jan; 25(1):98-104. PubMed ID: 18752928
[TBL] [Abstract][Full Text] [Related]
16. Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption.
Ness GC; Holland RC; Lopez D
Exp Biol Med (Maywood); 2006 May; 231(5):559-65. PubMed ID: 16636304
[TBL] [Abstract][Full Text] [Related]
17. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.
Thelen KM; Rentsch KM; Gutteck U; Heverin M; Olin M; Andersson U; von Eckardstein A; Björkhem I; Lütjohann D
J Pharmacol Exp Ther; 2006 Mar; 316(3):1146-52. PubMed ID: 16282522
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Robinson JG; Davidson MH
Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]